MGMT and glioblastoma: Furthermore, recent prospective randomized trials (NOA-08), the Nordic trial, and RTOG 0525 have shown MGMT promoter methylation can also be a useful predictive biomarker to stratify elderly GBM patients for RT versus chemotherapy with alkylating agents.